SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The $SLAP crypto community is highly active, frequently using the terms $WAGMI, $BROKE, and $RAGE to describe market sentiments. Discussions highlight the team's dedication and grind, referencing real-world partnerships and community efforts. There is also chatter about 'slapping the bears' suggesting bullish sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the community digests news around progress on the government shutdown, with potential implications for markets. Community members are actively debating whether the recent pullback represents a buying opportunity or a signal of deeper underlying issues, especially concerning AI valuations. Discussions also include analysis of potential market manipulation, technical indicators, and the influence of political factors.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders react to reports of a potential deal to end the government shutdown, anticipating a possible market rally. Community discussions revolve around the implications of the deal and a proposed $2000 stimulus check, with some questioning the sustainability of the rally and its effect on inflation. The ETF is also influenced by broader market sentiment, including tech valuations and upcoming economic data.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential catalysts like the end of the government shutdown and the possibility of an XRP ETF, with some anticipating significant price movement. Community members are weighing bullish and bearish scenarios, focusing on key support levels and potential resistance zones. Broader discussions include XRP's utility, regulatory landscape, and comparisons to other cryptocurrencies like BTC and ETH.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the OG meme coin, emphasizing its cultural significance. Community members are expressing their frustration with traditional financial systems and celebrating the return to the roots of meme culture. Bullish sentiment is high as the community focuses on building and pushing forward, encouraging others to join their movement.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions about market manipulation and its underlying valuation, particularly in light of substantial losses and alleged discrepancies between asset value and market cap. Community members are debating the stock's legitimacy, with some calling it a 'scam' and others defending it against criticism. Political debates surrounding Trump, the Republican party, and broader societal issues are also impacting the stock's narrative.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as community members discuss its potential for significant gains, drawing comparisons to other cryptocurrencies and highlighting its underlying technology. The community is actively discussing its potential for breaking resistance and reaching new price levels, as well as the upcoming mainnet launch. Broader conversations touch on COTI's role in privacy and its positioning within the cryptocurrency landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around a shared vision, highlighting the project's commitment and future potential. Despite market challenges, the community focuses on building and pushing forward, with a strong emphasis on unity and slapping down naysayers. Broke Perspective continues to release articles and information on the project, and it is sponsoring coverage of other projects as well.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending due to a recent partnership and a strategic collaboration, sparking optimism about the company's growth potential and its role in powering data centers. Community members are discussing the company's manufacturing expansion, revenue forecasts, and potential for significant upside, especially with government support and increasing AI-driven demand for energy storage. The stock is drawing comparisons to other high-growth companies, with some speculating about a potential short squeeze and significant price appreciation.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending as investors discuss the potential impact of Berkshire Hathaway's large cash position and AI-related investments. Community members are also analyzing technical indicators, such as moving averages and MACD crossovers, to gauge potential breakouts. Discussions also involve the possibility of a government shutdown resolution and its effect on markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM).The Summit Part 2 trial met its primary endpoint with a statistically significant placebo-adjusted improvement of 8.91 points in total symptom score (TSS) at 24 weeks.&nbsp;Patients treated with bezuclastinib saw a mean TSS reduction of 24.3 points, compared to 15.4 points for placebo.&nbsp;The drug also met all key secondary endpoints, including reductions in serum tryptase, with 87.4% of treated patients achieving at least a 50% drop versus none in the control group.&nbsp;Most adverse events were low-grade. Discontinuations due to side effects occurred in 5.9% of patients, all of whom recovered.H.C. Wainwright raised its price target to $22 from $12 and maintained a 'Buy' rating, raising its approval probability estimate to 95% from 60%, calling bezuclastinib a potential new standard of care.&nbsp;Jefferies lifted its target to $28 from $23 with a 'Buy' rating, citing a “home run” outcome and a $1 billion market opportunity in ISM alone.Leerink increased its target to $18 from $16 and reiterated an 'Outperform' rating, noting the safety profile exceeded expectations and pointing to strong positioning ahead of the Peak and Apex trial readouts due later in 2025.&nbsp;Baird took a more conservative view, raising its target to $9 from $7 while maintaining a 'Neutral' rating, stating that the results were better than the worst-case scenario but fell short of the best.Cogent remains on track to submit a new drug application (NDA) for bezuclastinib by year-end 2025 and will present detailed Summit findings at a medical conference later this year.Separately, Cogent announced a proposed public offering of $150 million in common stock.&nbsp;The company said proceeds will support continued development, regulatory and commercial preparation for bezuclastinib and other pipeline candidates, as well as general corporate purposes.&nbsp;On Stocktwits, retail sentiment for Cogent was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/COGT">Cogent’s stock</a> has risen 25.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple firms raised their price targets on Cogent Biosciences (COGT) following strong results from the Phase 3 Summit trial of bezuclastinib/Photo credit: Getty Images

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Equity

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options

Investors eyeing a purchase of Cogent Biosciences Inc (COGT) stock, but tentative about paying the going market price of 6.62/share, might benefit from considering selling puts among the...

Cogent Biosciences (COGT, $6.9) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that COGT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cogent Biosciences (COGT, $6.9) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that COGT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Cogent Biosciences files to sell 31.2M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cogent Biosciences (COGT, $6.72) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling COGT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cogent Biosciences (COGT, $6.72) Stochastic Oscillator left the oversold zone on March 28, 2024

This is a signal that COGT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$14.42
Prev Close	$14.72
Open	$14.68
Dividend Yield	0.00%
50-Day Moving Average	$14.40
Beta	1.49
Avg. Volume	2.31M
PE Ratio	-6.28

52-Week High	$17.15
52-Week Low	$3.72
Market Capitalization	$2.07B
EPS (Annual)	-$2.46
Price to Book	35.83
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

COGT
Cogent Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest COGT News

COGTCogent Biosciences Inc